BPC-157 Complete Drug-Drug Interaction Profile

Why is there no complete interaction profile?

BPC-157 is not an FDA-approved drug. No approved product contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's 2026 review found no approved product containing it in any country it searched [1]. There is no FDA-approved prescribing label for BPC-157, so there is no approved interaction, contraindication or monitoring section [1].

FDA's reviewers concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157, and found no human studies of it given by mouth, by subcutaneous injection, as a nasal spray or on the skin [1]. FDA identified five small human studies in total: meeting abstracts, a retrospective chart review, a single-arm pilot and a 2-person pilot [1]. A 2026 systematic review of human orthopaedic and regenerative use included 3 studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low [5]. A 2025 review that searched studies through June 2024 found no clinical safety data [7]; a later intravenous pilot included only 2 adults [4].

The three studies in the 2026 review were a retrospective chart review of intra-articular knee injections (17 patients, 16 followed up), a single-arm pilot of bladder-wall injections in 12 women, and a 2-person intravenous safety pilot [8][9][4]. The knee chart review included four patients who received BPC-157 together with thymosin beta-4; it did not test whether the two substances interacted [8].

How does BPC-157 behave in the body?

FDA found no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin [1]. After rectal enemas in two early studies the peptide was mostly not detectable in blood, which FDA read as it appearing not to be absorbed systemically by that route [1]. A 2025 review states that BPC-157 is metabolized in the liver with a half-life of less than 30 minutes and is cleared by the kidneys [7].

A rat study of BPC-157 with adrenergic and dopamine drugs

A 1997 rat study tested whether several adrenergic and dopamine drugs changed BPC-157's effect on stomach lesions [2]. BPC-157 was given at 10 micrograms or 10 nanograms per kilogram, intraperitoneally or intragastrically, before a 48-hour restraint-stress experiment, and other drugs were given at the same time [2]:

• phentolamine 10 mg/kg, clonidine 0.1 mg/kg and haloperidol 5 mg/kg fully abolished the protection [2];
• prazosin 0.5 mg/kg, yohimbine 5 mg/kg and domperidone 5 mg/kg did not affect it [2];
• atenolol 20 mg/kg abolished only the intraperitoneal protection, and propranolol 1 mg/kg affected only the intragastric protection [2].

The question in that study was whether other drugs change BPC-157's protective effect on stomach lesions in rats. It is an animal study and does not show what happens when these drugs are taken with BPC-157 by people [2].

Clotting: what the animal data show

FDA's review of 28-day intramuscular toxicity studies noted that BPC-157 shortened the activated partial thromboplastin time (aPTT) in rats and prolonged it in dogs, and raised ALT, glucose and triglyceride levels [1]. The clotting signal pointed in opposite directions in the two species, and longer studies and cancer-risk studies were not available [1].

A 2018 review describes rat experiments in which BPC-157 prevented the formation of, and reversed established, thrombosis in a surgically anastomosed abdominal aorta and after inferior vena cava occlusion, and attenuated bleeding prolongation and thrombocytopenia after amputation, with or without anticoagulants [3].

These are animal models with surgically created injury. They do not give a bleeding or clotting prediction for a person taking warfarin, apixaban, rivaroxaban, aspirin or clopidogrel [1][3].

Blood vessels and the nitric-oxide pathway

The same 2018 review reports that BPC-157 counteracted the effects of L-NAME and/or L-arginine in animal experiments [3]. What was measured was lesion and vessel behaviour in animals, not blood pressure in people taking ACE inhibitors, ARBs, calcium-channel blockers, beta-blockers, nitrates or PDE5 inhibitors [3].

The drug classes people ask about

For anticoagulants and antiplatelet drugs, NSAIDs, blood-pressure medicines, antidepressants, antipsychotics, opioids, GLP-1 receptor agonists, insulin, thyroid or sex hormones, transplant immunosuppressants and chemotherapy, the interaction-related findings on this page are limited to the animal work above: adrenergic and dopamine drugs blocking BPC-157's own effect in rats, and bleeding and vessel outcomes in surgically injured animals [2][3]. These findings do not establish that any named combination is safe, risky or dose-adjustable.

Why is there no dose or monitoring schedule?

There is no approved dose, cycle length, taper or monitoring panel, because there is no approved product [1]. Doses in the few published human reports were: rectal enema up to 2 mg/kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis; 2 to 4 mg injected into the knee once or twice; 10 mg injected around the bladder wall once; and 10 mg then 20 mg intravenously on two days in 2 healthy adults [1]. None of these is a recommended dose.

The 2026 regulatory activity did not change BPC-157's unapproved status. FDA staff proposed in July 2026 that BPC-157 not be added to the pharmacy bulks list [1]. The Pharmacy Compounding Advisory Committee then voted in favor of adding it, against that recommendation; the vote is advice only and BPC-157 is not on the list [10][11]. On October 28, 2026 HHS announced a draft enforcement-discretion policy for six peptides that covers BPC-157 acetate only and does not list nasal, rectal or intravenous forms [6][11]. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' [6]. Neither step is an approval.

What has been reported as a problem

FDA searched its adverse-event database through December 4, 2025 and found 3 reports, all for injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred when the person was exposed again to a BPC-157 plus TB-500 product [1]. FDA said it cannot tell whether BPC-157 caused any of them [1].

The October 2026 draft policy conditions say serious adverse events and quality problems with compounded BPC-157 are to be reported to FDA MedWatch [11].